TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12701671

Group type: EXPERIMENTAL
Intervention: alprazolam with pre-treatment of carbamazepine
Number of subjects: 123

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 123
Study: 10720509

Group type: EXPERIMENTAL
Intervention: Recombinant gp120 vaccines (various doses from SF‐2 or MN strains)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Adjuvant only
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Accelerated immunization schedule with lowest dose of SF‐2 vaccine
Number of subjects: 126
Study: 9189105

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendicectomy
Number of subjects: 108

Group type: COMPARATOR
Intervention: Conventional appendicectomy
Number of subjects: 108
Study: 8240640

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.2 mg initial injection, followed by 0.1 mg per minute until desired vigilance)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no flumazenil used)
Number of subjects: 24
Study: 3797990

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 24
Study: 29494171

Group type: EXPERIMENTAL
Intervention: Consideration of research staff demographics in psychological research
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ingroup versus outgroup effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stereotype and implicit bias effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Priming and social tuning effects
Number of subjects: 0
Study: 27354081

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin given from 11 to 13 weeks' gestation
Number of subjects: 1760

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1760
Study: 24884424

Group type: EXPERIMENTAL
Intervention: Pasteurized donor milk
Number of subjects: 363

Group type: COMPARATOR
Intervention: Preterm formula
Number of subjects: 363
Study: 22775424

Group type: EXPERIMENTAL
Intervention: Yoga training for 10 weeks
Number of subjects: 19
Study: 20045075

Group type: EXPERIMENTAL
Intervention: Alcohol (0.6g/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 18783962

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine therapy
Number of subjects: 60
Study: 15574625

Group type: EXPERIMENTAL
Intervention: Nonfasting ketogenic diet (NFKD)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Initial fasting ketogenic diet (IFKD)
Number of subjects: 41
Study: 11376516

Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 73
Study: 9211212

Group type: EXPERIMENTAL
Intervention: 1% aqueous beryllium sulfate (BeSO4)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 1% petrolatum beryllium sulfate (BeSO4)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 0.1% beryllium sulfate (BeSO4)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Beryllium patch test
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Biopsies at abnormal patch test sites
Number of subjects: 34
Study: 8247598

Group type: EXPERIMENTAL
Intervention: Pulmonary function tests (SVC, FVC, MVV)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Men's unforced adapted prediction equations
Number of subjects: 109
Study: 3675502

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Scopolamine 0.6 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Scopolamine 1 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: d-amphetamine 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Scopolamine 0.6 mg/d-amphetamine 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Scopolamine 1 mg/d-amphetamine 10 mg
Number of subjects: 8
Study: 28983705

Group type: EXPERIMENTAL
Intervention: Quarterly intravenous bisphosphonates (3 mg ibandronate every 3 months)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Weekly oral bisphosphonates (70 mg alendronate orally once each week for 12 months)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Weekly oral bisphosphonates (70 mg alendronate)
Number of subjects: 432
Study: 27274007

Group type: COMPARATOR
Intervention: Glyburide alone (period 0)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Piragliatin + glyburide (period 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Piragliatin alone (period 2)
Number of subjects: 0
Study: 25391692

Group type: EXPERIMENTAL
Intervention: FAST scan performed by paramedics
Number of subjects: 10
Study: 23782588

Group type: EXPERIMENTAL
Intervention: Tocilizumab 162 mg subcutaneously QW
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Tocilizumab 162 mg subcutaneously Q2W
Number of subjects: 29
Study: 21218651

Group type: EXPERIMENTAL
Intervention: Daily medication of low-dose tadalafil (5 mg/d for 6-8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 60
Study: 18226126

Group type: EXPERIMENTAL
Intervention: Antithrombin (3000 IU/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (Albumin 582 mg/day)
Number of subjects: 42
Study: 16773938

Group type: EXPERIMENTAL
Intervention: Immediate therapy for patients with moderate or high conversion risk (e.g. elderly age, greater intraocular pressure, central corneal thickness, greater cup/disc ratio)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thorough monitoring for patients without moderate or high conversion risk
Number of subjects: 0
Study: 12729083

Group type: EXPERIMENTAL
Intervention: Total-etch 2-step (TE2)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Total-etch 3-step (TE3)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Self-etch 2-step (SE2)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Self-etch 1-step (SE1)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Total-etch 3-step (TE3) and Self-etch 2-step (SE2)
Number of subjects: 44
Study: 10815792

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 8667057

Group type: EXPERIMENTAL
Intervention: CCK‐8 infusion (0.3 ng/kg per min for 60 min)
Number of subjects: 18

Group type: COMPARATOR
Intervention: CCK‐8 bolus injection (0.04 microgram/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CCK‐8 infusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: CCK‐8 bolus injection
Number of subjects: 18
Study: 1601759

Group type: EXPERIMENTAL
Intervention: Cefpirome 0.5 g
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefpirome 1.0 g
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefpirome 2.0 g
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefpirome 1.0 g every 12 h for 3.5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefpirome (all doses)
Number of subjects: 0
Study: 3968920

Group type: EXPERIMENTAL
Intervention: After-hours telephone access to physicians (S1 and S2)
Number of subjects: 1849

Group type: EXPERIMENTAL
Intervention: After-hours telephone access to physicians with computerized medical records (S2)
Number of subjects: 1849

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 1849
Study: 31715355

Group type: EXPERIMENTAL
Intervention: Test formulation of diclofenac diethylamine emulgels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference formulation of diclofenac diethylamine emulgels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both test and reference formulations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rheological properties of test and reference formulations
Number of subjects: 0
Study: 29482717

Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg/day
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Aspirin 1000 mg/day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 26695876

Group type: EXPERIMENTAL
Intervention: GTC‐NEX (780 mg GTC with water, no exercise)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GTC‐EX (780 mg GTC with exercise)
Number of subjects: 16

Group type: COMPARATOR
Intervention: PL‐EX (water only, with exercise)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: All groups (including GTC‐NEX, GTC‐EX, PL‐EX)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GTC‐NEX vs GTC‐EX
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Resting vs Exercise-induced BAP to d‐ROMs
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Resting vs Exercise-induced 8‐OHdG
Number of subjects: 16
Study: 24637183

Group type: EXPERIMENTAL
Intervention: Closed lateral internal sphincterotomy
Number of subjects: 136

Group type: COMPARATOR
Intervention: Open lateral sphincterotomy
Number of subjects: 136
Study: 23097636

Group type: EXPERIMENTAL
Intervention: Noni juice (29.5 mL to 188 mL daily)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo (fruit juice)
Number of subjects: 132
Study: 21179277

Group type: EXPERIMENTAL
Intervention: Post-visit group (additional visit after FB)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Control group (one visit before FB)
Number of subjects: 304
Study: 17958668

Group type: EXPERIMENTAL
Intervention: Peer-selected trained lay health workers (LHWs) on farms, mentored and managed by nurses.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effective intervention involving peer-selected LHWs.
Number of subjects: 0
Study: 15489105

Group type: EXPERIMENTAL
Intervention: Circulating progenitor cells (CPC)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Bone marrow-derived progenitor cells (BMC)
Number of subjects: 59

Group type: COMPARATOR
Intervention: CPC and BMC
Number of subjects: 59
Study: 11206252

Group type: EXPERIMENTAL
Intervention: Ankle disk training with adhesive tape
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ankle disk training without adhesive tape (Control)
Number of subjects: 22
Study: 9683366

Group type: EXPERIMENTAL
Intervention: Simultaneous radiation and chemotherapy (cis-DDP, 5-fluorouracil, leucovorin)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Nodal CT density
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Total tumor volume
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: MIB1-LI
Number of subjects: 87
Study: 7833224

Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 mg four times over 36 h)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 25
Study: 3339500

Group type: EXPERIMENTAL
Intervention: CSO‐110 (formula diet composed of casein, sucrose, dextrin with maltose, and vegetable oil providing 110 kcal/kg body weight/d)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: CSO‐55 (providing 55 kcal/kg/d for 2 days, then CSO‐110)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Oral glucose‐electrolyte solution (GES) for 2 days, then CSO‐55 for 2 days, then CSO‐110
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Intravenous GES for the first 2 days, then same diets as Group 3
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: CSO diets during the early phase of therapy
Number of subjects: 128
Study: 31941471

Group type: EXPERIMENTAL
Intervention: Sit-to-stand desks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular desks (Control)
Number of subjects: 0
Study: 28787250

Group type: EXPERIMENTAL
Intervention: Virtual visits for Parkinson's disease
Number of subjects: 149
Study: 27177865

Group type: EXPERIMENTAL
Intervention: Arm A: Radiation therapy (70 Gy), concurrent cetuximab, and concurrent pemetrexed
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Arm B: Identical regimen as Arm A plus concurrent bevacizumab followed by bevacizumab maintenance for 24 weeks
Number of subjects: 78

Group type: COMPARATOR
Intervention: Historical control
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL) assessment
Number of subjects: 78
Study: 25425504

Group type: EXPERIMENTAL
Intervention: TIDES intervention group
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 200
Study: 24351113

Group type: EXPERIMENTAL
Intervention: Blended learning approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Didactic approach
Number of subjects: 0
Study: 20966405

Group type: EXPERIMENTAL
Intervention: Treadmill exercise (TM)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Supervised stretching (CONTROL)
Number of subjects: 53
Study: 18238878

Group type: EXPERIMENTAL
Intervention: Diazepam 10‐mg autoinjector
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2 diazepam 10‐mg autoinjectors (20 mg) administered simultaneously
Number of subjects: 24
Study: 16788711

Group type: EXPERIMENTAL
Intervention: Hypoxic exercise (HG)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normoxic exercise (NG)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hypoxic group (HG) after training
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normoxic group (NG) after training
Number of subjects: 14
Study: 12679900

Group type: EXPERIMENTAL
Intervention: Pre-operative transcatheter arterial chemoembolization (TACE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-operative transcatheter arterial chemoembolization (TACE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adoptive immunotherapy using LAK cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon α and Interferon β
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acyclic retinoic acid
Number of subjects: 0
Study: 15090417

Group type: EXPERIMENTAL
Intervention: 50% autologous serum drops
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 16
Study: 10396714

Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron
Number of subjects: 3027

Group type: EXPERIMENTAL
Intervention: 0.625 mg droperidol
Number of subjects: 3027

Group type: EXPERIMENTAL
Intervention: Prophylaxis (ondansetron or droperidol)
Number of subjects: 3027

Group type: EXPERIMENTAL
Intervention: Individualized outcome feedback
Number of subjects: 3027

Group type: EXPERIMENTAL
Intervention: Prophylaxis
Number of subjects: 3027

Group type: EXPERIMENTAL
Intervention: PROT selection
Number of subjects: 3027

Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 3027
Study: 7562289

Group type: EXPERIMENTAL
Intervention: Physical activity program (group EX; n = 13), consisting of range of motion with passive resistance to all extremities for 5 to 10 minutes daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (group C; n = 13)
Number of subjects: 26
Study: 2256469

Group type: EXPERIMENTAL
Intervention: Ciclosporin (CS) at low doses (not exceeding 5 mg/kg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciclosporin (CS)
Number of subjects: 0
Study: 7378228

Group type: EXPERIMENTAL
Intervention: 20-gauge Teflon cannulae
Number of subjects: 333

Group type: COMPARATOR
Intervention: Other cannula types
Number of subjects: 333
Study: 28392142

Group type: EXPERIMENTAL
Intervention: PCV-13 booster
Number of subjects: 62

Group type: COMPARATOR
Intervention: PCV-13
Number of subjects: 62
Study: 26316025

Group type: EXPERIMENTAL
Intervention: Group-1 (level 1) attended an educational group session (EGS) on the Mediterranean diet (MD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group-2 (level 2) attended an EGS and received additional support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined sample from both groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost of food intake during intervention
Number of subjects: 0
Study: 23335178

Group type: EXPERIMENTAL
Intervention: HPV16 DNA methylation score (mean methylation in L1 and any methylation in L2)
Number of subjects: 84
Study: 21392068

Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Combined motivational enhancement and cognitive behaviour therapy
Number of subjects: 344

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 344
Study: 20307457

Group type: EXPERIMENTAL
Intervention: Steroid injection to heel
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Local anaesthetic block to tibial nerve
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 45
Study: 17338716

Group type: EXPERIMENTAL
Intervention: Pacemaker or cardioverter‐defibrillator implantation
Number of subjects: 150

Group type: COMPARATOR
Intervention: Baseline ICV
Number of subjects: 150
Study: 15569121

Group type: EXPERIMENTAL
Intervention: Bacillus clausii (2 x 10(9) spores, t.d.s. for 14 days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (t.d.s. for 14 days)
Number of subjects: 120
Study: 11512649

Group type: EXPERIMENTAL
Intervention: Alfentanil 20 microg x kg(‐1)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Alfentanil 25 microg x kg(‐1)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Alfentanil 30 microg x kg(‐1)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Alfentanil 10 microg x kg(‐1) and suxamethonium 1 mg x kg(‐1)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Group SSA (alfentanil 10 microg x kg(‐1) and suxamethonium 1 mg x kg(‐1))
Number of subjects: 4
Study: 9780987

Group type: EXPERIMENTAL
Intervention: Laparoscopic splenectomy (LS)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Open splenectomy (OS)
Number of subjects: 82
Study: 8172150

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg at bedtime for 2 months
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg at bedtime for 2 months
Number of subjects: 16
Study: 3280795

Group type: EXPERIMENTAL
Intervention: Auranofin (AF) at a daily dose of 4 mg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Auranofin (AF) at a daily dose of 6 mg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Auranofin (AF) at a daily dose of 8 mg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Auranofin (AF) at a daily dose above 6 mg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Long-term treatment with Auranofin (AF)
Number of subjects: 58
Study: 31117810

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 18924

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924
Study: 27792836

Group type: EXPERIMENTAL
Intervention: 1 g paracetamol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 26353031

Group type: EXPERIMENTAL
Intervention: Infliximab plus IVIG
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo/IVIG
Number of subjects: 190
Study: 23356772

Group type: EXPERIMENTAL
Intervention: GAKIC (10.2 g)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: GAKIC
Number of subjects: 9
Study: 20617887

Group type: EXPERIMENTAL
Intervention: First presentation of items
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated presentations of items
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New items
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cortical regions (left retrosplenial/posterior cingulate cortex and right lateral occipito-temporal cortex)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bilateral mid-intraparietal sulcus and precuneus
Number of subjects: 0
Study: 18854418

Group type: EXPERIMENTAL
Intervention: Intermittent renal replacement therapy (IRRT)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Continuous renal replacement therapy (CRRT)
Number of subjects: 316
Study: 17823012

Group type: EXPERIMENTAL
Intervention: Periarticular injections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patient-controlled analgesia with or without femoral nerve block (TKA patients)
Number of subjects: 0
Study: 15183925

Group type: EXPERIMENTAL
Intervention: Caffeine and glucose drink (68 g carbohydrate and 38 mg caffeine)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Caffeine and glucose drink (68 g carbohydrate and 46 mg caffeine)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Caffeine and glucose drink (60 g carbohydrate and 33 mg caffeine)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 56
Study: 12427583

Group type: EXPERIMENTAL
Intervention: Naltrexone with medically-based psychosocial intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with medically-based psychosocial intervention
Number of subjects: 0
Study: 9814488

Group type: EXPERIMENTAL
Intervention: Acute oral water load test (20 mL/kg BW) in patients with water retention
Number of subjects: 17

Group type: COMPARATOR
Intervention: Acute oral water load test (20 mL/kg BW) in normal subjects
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: UAQP‐2 levels in patients with water retention
Number of subjects: 17

Group type: COMPARATOR
Intervention: UAQP‐2 levels in normal subjects
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Minimal urinary osmolality in patients with water retention
Number of subjects: 17

Group type: COMPARATOR
Intervention: Minimal urinary osmolality in normal subjects
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Hydrocortisone replacement in patients with hypopituitarism
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: UAQP‐2 levels after hydrocortisone replacement in patients with hypopituitarism
Number of subjects: 17

Group type: COMPARATOR
Intervention: UAQP‐2 levels in control subjects
Number of subjects: 17
Study: 7897461

Group type: EXPERIMENTAL
Intervention: Rehabilitation Activities Profile (RAP) assessment
Number of subjects: 0
Study: 2612550

Group type: EXPERIMENTAL
Intervention: C‐F 5 mg b.d.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ER‐F 10 mg o.d.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 745897

Group type: EXPERIMENTAL
Intervention: Mental rehearsal only
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mental rehearsal with simulated dart-throwing motor movements
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Direct physical practice
Number of subjects: 32

Group type: COMPARATOR
Intervention: No-practice controls
Number of subjects: 32
Study: 31526039

Group type: EXPERIMENTAL
Intervention: MediYoga
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control
Number of subjects: 132

Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 132